We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




AI May Improve Diagnostic Interpretation of Lung Function Tests

By LabMedica International staff writers
Posted on 12 Sep 2016
Print article
Image: Artificial Intelligence (AI) can be used to help improve the accuracy of the diagnosis in lung diseases (Photo courtesy of the IANS).
Image: Artificial Intelligence (AI) can be used to help improve the accuracy of the diagnosis in lung diseases (Photo courtesy of the IANS).
A first study in the field of lung testing suggests that diagnosis of long-term lung diseases could be improved using artificial intelligence (AI) algorithms developed to interpret results compiled from currently used tests.

The study, presented September 4 at the European Respiratory Society's International Congress (London, UK, September 3-7, 2016), is the first to explore the potential use of AI for improving accuracy of diagnosis of lung diseases. Current testing requires a series of assays including a spirometry test (measures the volume amount and the flow speed of air during breathing), followed by a body plethysmography test (measures static lung volumes and airways resistance), then finally a diffusion test (measures amount of oxygen and other gases that cross the lungs' air sacs). Analysis of the results of these tests is largely based on expert opinion and international guidelines, attempting to detect patterns.

The new study included data from 968 people who were undergoing complete lung function testing for the first time. All participants received a first clinical diagnosis based on lung function tests and additional tests (e.g. CT scans, electrocardiogram, etc.). Final diagnosis was validated by a consensus of the large group of expert clinicians.

The researchers subsequently investigated whether “machine learning” (utilizing algorithms that can learn from data analysis and perform predictions) could be used to effectively analyze a complete set of lung function tests. They developed an algorithm process in addition to the routine lung function parameters and clinical variables of smoking history, body mass index, and age. Based on the pattern of both the clinical and lung function data, the algorithm provided a suggestion for the most likely diagnosis.

Wim Janssens from University of Leuven (Leuven, Belgium), study senior author, said: "We have demonstrated that AI can provide us with a more accurate diagnosis in this new study. The beauty of our development is that the algorithm can simulate the complex reasoning that a clinician uses to give their diagnosis, but in a more standardized and objective way."

Clinicians currently rely on analyzing the results using population-based parameters. With AI, the machine can observe a combination of patterns simultaneously to help produce a more accurate diagnosis. This has been done in other healthcare fields, such as with an automated interpretation of results from an electrocardiogram being routinely used in clinical practice as a decision support system.

Marko Topalovic, University of Leuven, study first author, said: "The benefit of this method is a more accurate and automated interpretation of pulmonary function tests, and thus better disease detection. Not only can this help non-experienced clinicians, but it also has many benefits for healthcare overall as it is time saving in achieving a final diagnosis as it could decrease the number of redundant additional tests clinicians are taking to confirm the diagnosis."

The next step will be to test the algorithm in different populations and increase the system’s decision power using continuous updates on lung function data with validated clinical diagnoses.

Related Links:
University of Leuven

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.